Earnings ·
Reports Q3 revenue of $98.3M, up 18%, and reaffirms full-year guidance
PRCTPROCEPT BioRobotics Corp
PROCEPT BioRobotics reported third-quarter 2026 total revenue of $98.3 million, an 18% increase from the prior year period, driven by a 21% rise in U.S. handpiece and consumable sales to $53.9 million and a 32% jump in international revenue to $12.5 million. The company performed over 13,400 U.S. procedures, reflecting 22% growth, while delivering 62 HYDROS systems with an average selling price of approximately $495,000. Gross margin improved slightly to 66%, though the net loss widened to $26.5 million from $21.4 million a year earlier as operating expenses rose to $92.5 million due to continued investment in product development and sales. The company reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and reiterated an adjusted EBITDA loss range of $30 million to $35 million. PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.